GFAP and non-small cell lung carcinoma: Biomarkers of neurodegeneration, NfL, GFAP, tau and UCHL1 were measured in a cohort of up to 88 subjects at baseline and 21 days after the first of six cycles of paclitaxel and carboplatin chemotherapy, administered as therapy for the treatment of non-small cell lung cancer.